Advarra, a leading provider of regulatory reviews and clinical research technology, has launched Braid, an AI-powered engine designed to optimise the design and execution of clinical trials. Built on one of the most comprehensive clinical trial operations datasets in the industry, Braid generates insights and powers automation across multiple systems, enabling sponsors, CROs, and sites to streamline processes and improve decision making.

The platform draws on operational data from more than 30,000 studies conducted by 3,500 sponsors, integrating cycle times, enrolment trends, and study modifications with protocol-related documents. By harmonising this data with standardised ontologies, Braid delivers analytical and automation capabilities that allow trial teams to anticipate challenges and reduce operational inefficiencies.

Advarra executives noted that the tool addresses a long-standing challenge in the sector: the difficulty of accessing and structuring operational data buried in study documents and disparate systems. Braid captures milestones throughout the trial lifecycle, offering dynamic intelligence to improve planning, execution, and scalability.

The company is rolling out its first Braid-powered solution aimed at enhancing study design. This offering will provide data-driven insights to flag overly complex visit schedules, identify restrictive eligibility criteria, and recommend startup timelines based on historical performance—helping reduce cost, timelines, and participant burden.

Advarra emphasised that while AI will streamline operations, decisions related to ethical review and patient protection will remain firmly with people. The company said its approach prioritises innovation balanced with trust, ethics, and scientific rigour.

Trusted by top global biopharma sponsors, CROs, and thousands of investigators, Advarra plans to expand the application of Braid across multiple use cases, with the goal of accelerating trials and connecting stakeholders in a more integrated research ecosystem.